About: A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies
Creator	Brochot, Etienne Castelain, Sandrine Duverlie, Gilles François, Catherine Wychowski, Czeslaw Capron, Dominique Dedeurwaerder, Sarah Fournier, Carole Schnuriger, Aurelie Thibault, Vincent
Source	Medline; PMC
abstract	BACKGROUND/AIM: The role of humoral immunity in hepatitis C virus (HCV) infection is poorly understood. Nevertheless, there is increasing interest in characterizing the neutralizing antibodies in the serum of HCV-infected patients. Focus reduction assays have been widely used to evaluate neutralizing antibody responses against a range of non-cytopathic viruses. Based on the recent development of a HCV cell culture system using the genotype 2 JFH-1-strain, we developed a focus reduction assay for HCV-neutralizing antibodies. METHODS: The focus reduction assay was based on a standard microneutralization assay in which immunostained foci on tissue culture plates are counted. The neutralizing anti-HCV antibodies titers of purified serum immunoglobulin samples from seventy-seven individuals were determined using a 50% focus reduction neutralization assay. Each titer was determined as the log value of the reciprocal antibody dilution that reduced the number of viral foci by 50%. IgG antibodies were first purified from each serum in order to avoid the facilitating effect of HDL on HCV entry. RESULTS: The assay's cut-off using an ELISA and RNA HCV-negative samples was found to be 1.25 log, corresponding to a dilution of 1:18. The assay was compared with a commercial HCV ELISA and exhibited specificity and sensitivity values of 100% and 96.5%, respectively, and good reproducibility (with intra-assay and inter-assay coefficients of variation of 6.7% and 12.6%, respectively). The assay did not show any cross-reactivity with anti-HIV, anti-HBs or heterophile antibody-positive samples. The neutralizing antibodies titers were 2.13 log (1:134) for homologous samples from HCV genotype 2 infected patients harboring the same genotype as JFH-1 and 1.93 log (1:85) for heterologous samples from patients infected by genotypes other than type 2. These results confirm the presence of broadly cross-neutralizing antibodies already reported using the HCV pseudoparticles system. CONCLUSION: This study presents a simple, specific and reproducible cell culture-based assay for determination of HCV-neutralizing antibodies in human sera. The assay should be an important tool for gauging the relationship between the neutralizing antibodies response and viral load kinetics in acutely or chronically infected patients and for investigating the possible eradication or prevention of HCV infection by neutralizing antibodies.
has issue date	2007-03-30(xsd:dateTime)
bibo:doi	10.1186/1743-422x-4-35
bibo:pmid	17397531
has license	cc-by
sha1sum (hex)	ee8dca216514deeed4c9415bc2ad8a78dc3d9670
schema:url	https://doi.org/10.1186/1743-422x-4-35
resource representing a document's title	A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies
has PubMed Central identifier	PMC1852297
has PubMed identifier	17397531
schema:publication	Virol J
resource representing a document's body	covid:ee8dca216514deeed4c9415bc2ad8a78dc3d9670#body_text
is schema:about of	named entity 'reduction' named entity 'humoral immunity' named entity 'neutralization' covid:arg/ee8dca216514deeed4c9415bc2ad8a78dc3d9670 named entity 'strain' named entity 'Nevertheless' named entity 'focus' named entity 'HCV' named entity 'genotype' named entity 'neutralizing antibodies' named entity 'neutralizing antibodies' named entity 'hepatitis C virus (HCV) infection' named entity 'neutralizing antibody' named entity 'neutralizing antibodies' named entity 'France' named entity 'cell culture' named entity 'genotype' named entity 'epitopes' named entity 'High Wycombe' named entity 'statistically significant' named entity 'antiviral therapy' named entity 'host factors' named entity 'HCV genotypes' named entity 'cell line' named entity '37°C' named entity 'HCV' named entity 'experimental animal' named entity 'genotype' named entity 'homologous' named entity 'culture medium' named entity 'HCV' named entity 'antigenicity' named entity 'Corning, NY' named entity 'serum samples' named entity 'HCV' named entity 'Serum' named entity 'viral strain' named entity 'HCV' named entity 'genotype' named entity 'complement' named entity 'culture medium' named entity 'antibody' named entity 'virions' named entity 'chimpanzee' named entity 'cirrhosis' named entity 'genotype' named entity 'cross-reactivity' named entity 'HCV' named entity 'regression analysis' named entity 'HCV' named entity 'distilled water' named entity 'heterophile antibodies' named entity 'France' named entity 'United Kingdom' named entity 'genotypes' named entity 'genotypes' named entity 'cell culture' named entity 'HCV' named entity 'Huh-7' named entity 'neutralizing antibodies' named entity 'cDNA' named entity 'cell culture' named entity 'HCV' named entity 'hepatitis' named entity 'HCV' named entity 'HCV' named entity 'scavenger receptor BI' named entity 'microtiter plates' named entity 'cell culture' named entity 'HCV' named entity 'titer' named entity 'infection'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software